Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical systems for glaucoma and retinal diseases, has reported its financial results for the second quarter ended June 28, 2025. The company generated total revenue of $13.6 million, marking a 7% year-over-year increase and a 14% sequential growth from the first quarter of 2025. The Cyclo G6® product family revenue remained steady at $3.3 million year-over-year. The company sold 13,100 Cyclo G6 probes, down from 15,100 in the prior year quarter, while sales of Cyclo G6 Glaucoma Laser Systems increased to 35 units from 28 units in the previous year quarter. The gross profit for the quarter was $4.7 million, corresponding to a 34.5% gross margin, which is a decrease from the $5.1 million, or 40.7% gross margin, reported in Q2 2024. This decline was attributed to increased manufacturing costs and a shift in product and geographic sales mix. Operating expenses were reduced by 28% to $5.6 million due to cost-cutting measures initiated in late 2024. Iridex reported a net loss of $1.0 million for Q2 2025, compared to a net loss of $2.7 million in the same period of the previous year. Non-GAAP adjusted EBITDA showed a significant improvement, reaching $21 thousand, compared to a loss of $1.7 million in Q2 2024. The company aims to achieve cash flow breakeven and positive adjusted EBITDA in 2025, with revenue levels consistent with those in 2024. Iridex's management is focused on refining its business model to enhance profitability and maintain a competitive market position.